The oral mucosa immune environment and oral transmission of HIV/SIV

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 34-53

  Wood, Lianna F ^a,b,c   Chahroudi, Ann ^d   Chen, Hui Ling ^a,c   Jaspan, Heather B ^a,e   Sodora, Donald L ^a,c  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; Inflammation; Mucosal immunity; Oral transmission; SIV; SIV natural hosts

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; BREAST MILK; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; MOUTH INFLAMMATION; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

ADAPTIVE IMMUNITY; ADULT; AGE FACTORS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFANT; INFANT, NEWBORN; INFLAMMATION; MOUTH MUCOSA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84879294545     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12078     Document Type: Article

References (285)

1. McElrath MJ. Standing guard at the mucosa. Immunity 2011;34:146-148.
2. Spetz AL, Chiodi F. Reduction of HIV-1 load in semen during follow-up study of RV144 vaccine trial boosts interest for novel correlates of immune protection in genital mucosa. J Infect Dis 2012;207:1189-1192.
3. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012, 2012.
4. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006;6:726-732.
5. WHO. HIV Transmission Through Breastfeeding: A Review of the Available Evidence: 2007 Update. Geneva, Switzerland: WHO Press, 2008.
6. Coates RA, et al. Risk factors for HIV infection in male sexual contacts of men with AIDS or an AIDS-related condition. Am J Epidemiol 1988;128:729-739.
7. Darrow WW, et al. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health 1987;77:479-483.
8. Kingsley LA, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet 1987;1:345-349.
9. Lyman D, Winkelstein W, Ascher M, Levy JA. Minimal risk of transmission of AIDS-associated retrovirus infection by oral-genital contact. JAMA 1986;255:1703.
10. Mayer KH, Ayotte D, Groopman JE, Stoddard AM, Sarngadharan M, Gallo R. Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med 1986;80:357-363.
11. McCusker J, Stoddard AM, Mayer KH, Cowan DN, Groopman JE. Behavioral risk factors for HIV infection among homosexual men at a Boston community health center. Am J Public Health 1988;78:68-71.
12. Ostrow DG, DiFranceisco WJ, Chmiel JS, Wagstaff DA, Wesch J. A case-control study of human immunodeficiency virus type 1 seroconversion and risk-related behaviors in the Chicago MACS/CCS Cohort, 1984-1992. Multicenter AIDS Cohort Study. Coping and Change Study. Am J Epidemiol 1995;142:875-883.
13. Schechter MT, et al. The vancouver lymphadenopathy-AIDS study: 6. HIV seroconversion in a cohort of homosexual men. CMAJ 1986;135:1355-1360.
14. van Griensven GJ, et al. Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987;125:1048-1057.
15. Winkelstein W Jr, et al. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA 1987;257:321-325.
16. Gilbart VL, Evans BG, Dougan S. HIV transmission among men who have sex with men through oral sex. Sex Transm Infect 2004;80:324.
17. Page-Shafer K, et al. Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS 2002;16:2350-2352.
18. Page-Shafer K, Veugelers PJ, Moss AR, Strathdee S, Kaldor JM, van Griensven GJ. Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol 1997;146:531-542.
19. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999;150:306-311.
20. Wallace JI, Porter J, Weiner A, Steinberg A. Oral sex, crack smoking, and HIV infection among female sex workers who do not inject drugs. Am J Public Health 1997;87:470.
21. Baba TW, et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994;10:351-357.
22. Baba TW, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 1996;272:1486-1489.
23. Durudas A, Milush JM, Chen HL, Engram JC, Silvestri G, Sodora DL. Elevated levels of innate immune modulators in lymph nodes and blood are associated with more-rapid disease progression in simian immunodeficiency virus-infected monkeys. J Virol 2009;83:12229-12240.
24. Milush JM, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004;18:2371-2380.
25. Milush JM, Stefano-Cole K, Schmidt K, Durudas A, Pandrea I, Sodora DL. Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques. J Virol 2007;81:6175-6186.
26. Ziegler JB, Cooper DA, Johnson RO, Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1985;1:896-898.
27. Nduati R, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167-1174.
28. Kilewo C, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009;52:406-416.
29. Gaur AH, et al. Practice of feeding premasticated food to infants: a potential risk factor for HIV transmission. Pediatrics 2009;124:658-666.
30. Ivy W 3rd, et al. Premastication as a route of pediatric HIV transmission: case-control and cross-sectional investigations. J Acquir Immune Defic Syndr 2012;59:207-212.
31. Kuhn L, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS ONE 2007;2:e1363.
32. Iliff PJ, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005;19:699-708.
33. Kafulafula G, et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010;53:6-13.
34. Newell ML. Infant feeding and HIV-1 transmission. Lancet 1999;354:442-443.
35. Richardson BA, Hughes JP. Modeling breastmilk infectivity in HIV-1 infected mothers. Biometrics 2003;59:179-185.
36. Coovadia HM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007;369:1107-1116.
37. Taha TE, et al. Late postnatal transmission of HIV-1 and associated factors. J Infect Dis 2007;196:10-14.
38. Lunney KM, et al. Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. Clin Infect Dis 2010;50:762-769.
39. Neveu D, et al. Cumulative exposure to cell-free HIV in breast milk, rather than feeding pattern per se, identifies postnatally infected infants. Clin Infect Dis 2011;52:819-825.
40. Gantt S, et al. Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol 2010;84:10812-10819.
41. Koulinska IN, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 2006;41:93-99.
42. Phiri W, et al. Factors influencing breast milk HIV RNA viral load among Zambian women. AIDS Res Hum Retroviruses 2006;22:607-614.
43. Semba RD, et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994;343:1593-1597.
44. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 1999;354:471-476.
45. Kumwenda NI, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008;359:119-129.
46. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011;11:171-180.
47. Bedri A, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008;372:300-313.
48. Moorthy A, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 2009;4:e4096.
49. Zeh C, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011;8:e1000430.
50. Marmor M, et al. Possible female-to-female transmission of human immunodeficiency virus. Ann Intern Med 1986;105:969.
51. Monzon OT, Capellan JM. Female-to-female transmission of HIV. Lancet 1987;2:40-41.
52. Perry S, Jacobsberg L, Fogel K. Orogenital transmission of human immunodeficiency virus (HIV). Ann Intern Med 1989;111:951-952.
53. Rich JD, Buck A, Tuomala RE, Kazanjian PH. Transmission of human immunodeficiency virus infection presumed to have occurred via female homosexual contact. Clin Infect Dis 1993;17:1003-1005.
54. Spitzer PG, Weiner NJ. Transmission of HIV infection from a woman to a man by oral sex. N Engl J Med 1989;320:251.
55. Berrey MM, Shea T. Oral sex and HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:475.
56. Chen W, Samarasinghe PL. Allergy, oral sex, and HIV. Lancet 1992;339:627-628.
57. DeGruttola V, Mayer KH. Human immunodeficiency virus and oral intercourse. Ann Intern Med 1987;107:428-429.
58. Detels R, et al. Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. J Acquir Immune Defic Syndr 1989;2:77-83.
59. Edwards SK, White C. HIV seroconversion illness after orogenital contact with successful contact tracing. Int J STD AIDS 1995;6:50-51.
60. Goldberg DJ, Green ST, Kennedy DH, Emslie JA, Black JD. HIV and orogenital transmission. Lancet 1988;2:1363.
61. Keet IP, Albrecht vLN, Sandfort TG, Coutinho RA, Van Griensven GJ. Orogenital sex and the transmission of HIV among homosexual men. AIDS 1992;6:223-226.
62. Lane HC, Holmberg SD, Jaffe HW. HIV seroconversion and oral intercourse. Am J Public Health 1991;81:658.
63. Lifson AR, O'Malley PM, Hessol NA, Buchbinder SP, Cannon L, Rutherford GW. HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. Am J Public Health 1990;80:1509-1511.
64. Murray AB, Greenhouse PR, Nelson WL, Norman JE, Jeffries DJ, Anderson J. Coincident acquisition of Neisseria gonorrhoeae and HIV from fellatio. Lancet 1991;338:830.
65. Richters J, Grulich A, Ellard J, Hendry O, Kippax S. HIV transmission among gay men through oral sex and other uncommon routes: case series of HIV seroconverters, Sydney. AIDS 2003;17:2269-2271.
66. Robinson EK, Evans BG. Oral sex and HIV transmission. AIDS 1999;13:737-738.
67. Rozenbaum W, Gharakhanian S, Cardon B, Duval E, Coulaud JP. HIV transmission by oral sex. Lancet 1988;1:1395.
68. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-264.
69. Truong HM, Berrey MM, Shea T, Diem K, Corey L. Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. J Acquir Immune Defic Syndr 2002;29:232-243.
70. Padian N. Transmission of HIV possibly associated with exposure of mucous membrane to contaminated blood. MMWR Morb Mortal Wkly Rep 1997;46:620-623.
71. Dassey D, et al. HIV and orogenital transmission. Lancet 1988;2:1023-1024.
72. Greenhouse P. Female-to-female transmission of HIV. Lancet 1987;2:401-402.
73. Spencer B. Orogenital sex and risk of transmission of HIV. Lancet 1993;341:441.
74. Ou CY, et al. Molecular epidemiology of HIV transmission in a dental practice. Science 1992;256:1165-1171.
75. Fischl MA, Dickinson GM, Scott GB, Klimas N, Fletcher MA, Parks W. Evaluation of heterosexual partners, children, and household contacts of adults with AIDS. JAMA 1987;257:640-644.
76. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W Jr. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-1989. J Acquir Immune Defic Syndr 1993;6:303-312.
77. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994;331:341-346.
78. del Romero J, et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 2002;16:1296-1297.
79. Schwarcz SK, Kellogg TA, Kohn RP, Katz MH, Lemp GF, Bolan GA. Temporal trends in human immunodeficiency virus seroprevalence and sexual behavior at the San Francisco municipal sexually transmitted disease clinic, 1989-1992. Am J Epidemiol 1995;142:314-322.
80. Silvestre AJ, Kingsley LA, Wehman P, Dappen R, Ho M, Rinaldo CR. Changes in HIV rates and sexual behavior among homosexual men, 1984 to 1988/92. Am J Public Health 1993;83:578-580.
81. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010;39:1048-1063.
82. Boily MC, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009;9:118-129.
83. Hughes JP, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012;205:358-365.
84. Keele BF, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009;206:1117-1134.
85. Ma ZM, et al. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses 2011;27:1259-1269.
86. Stone M, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010;84:7083-7095.
87. Chenine AL, et al. Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 2010;201:1155-1163.
88. Van Rompay KK, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998;177:1247-1259.
89. Stahl-Hennig C, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999;285:1261-1265.
90. Tenner-Racz K, et al. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci USA 2004;101:3017-3022.
91. Abel K, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006;80:6357-6367.
92. Kosub DA, et al. Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques. Curr HIV Res 2008;6:520-530.
93. Durudas A, et al. Differential innate immune responses to low or high dose oral SIV challenge in Rhesus macaques. Curr HIV Res 2011;9:276-288.
94. Zhang Z, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999;286:1353-1357.
95. Zhang ZQ, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci USA 2004;101:5640-5645.
96. Li Q, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009;458:1034-1038.
97. Miller CJ, Abel K. Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6. J Med Primatol 2005;34:271-281.
98. Pudney J, Oneta M, Mayer K, Seage G 3rd, Anderson D. Pre-ejaculatory fluid as potential vector for sexual transmission of HIV-1. Lancet 1992;340:1470.
99. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 1997;176:960-968.
100. Satomi M, et al. Transmission of macrophage-tropic HIV-1 by breast-milk macrophages via DC-SIGN. J Infect Dis 2005;191:174-181.
101. Heath L, et al. Restriction of HIV-1 genotypes in breast milk does not account for the population transmission genetic bottleneck that occurs following transmission. PLoS ONE 2010;5:e10213.
102. Lewis P, et al. Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis 1998;177:34-39.
103. Pillay K, Coutsoudis A, York D, Kuhn L, Coovadia HM. Cell-free virus in breast milk of HIV-1-seropositive women. J Acquir Immune Defic Syndr 2000;24:330-336.
104. Rousseau CM, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003;187:741-747.
105. Salazar-Gonzalez JF, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol 2011;85:2751-2763.
106. Thiry L, et al. Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. Lancet 1985;2:891-892.
107. Ongradi J, Ceccherini-Nelli L, Pistello M, Specter S, Bendinelli M. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 1990;6:1433-1436.
108. Tugizov SM, et al. Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol 2012;86:2556-2570.
109. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997;3:42-47.
110. Bourinbaiar AS, Phillips DM. Transmission of human immunodeficiency virus from monocytes to epithelia. J Acquir Immune Defic Syndr 1991;4:56-63.
111. Phillips DM, Bourinbaiar AS. Mechanism of HIV spread from lymphocytes to epithelia. Virology 1992;186:261-273.
112. Tugizov SM, et al. HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology 2011;409:211-222.
113. Andreotti M, et al. Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique. AIDS Res Hum Retroviruses 2009;25:707-711.
114. Lehman DA, et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 2008;22:1475-1485.
115. Shapiro RL, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005;192:713-719.
116. Valea D, et al. CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology 2011;8:34.
117. Rousseau CM, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004;190:1880-1888.
118. Kumar RB, Maher DM, Herzberg MC, Southern PJ. Expression of HIV receptors, alternate receptors and co-receptors on tonsillar epithelium: implications for HIV binding and primary oral infection. Virol J 2006;3:25.
119. Maher D, Wu X, Schacker T, Larson M, Southern P. A model system of oral HIV exposure, using human palatine tonsil, reveals extensive binding of HIV infectivity, with limited progression to primary infection. J Infect Dis 2004;190:1989-1997.
120. Maher DM, Zhang ZQ, Schacker TW, Southern PJ. Ex vivo modeling of oral HIV transmission in human palatine tonsil. J Histochem Cytochem 2005;53:631-642.
121. Alfsen A, Yu H, Magerus-Chatinet A, Schmitt A, Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005;16:4267-4279.
122. Han Y, Ventura CL, Black KP, Cummins JE Jr, Hall SD, Jackson S. Productive human immunodeficiency virus-1 infection of epithelial cell lines of salivary gland origin. Oral Microbiol Immunol 2000;15:82-88.
123. Liu X, et al. Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes. J Virol 2003;77:3470-3476.
124. Meng G, et al. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med 2002;8:150-156.
125. Delezay O, et al. Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29. AIDS 1997;11:1311-1318.
126. Kage A, et al. Epithelial uptake and transport of cell-free human immunodeficiency virus type 1 and gp120-coated microparticles. J Virol 1998;72:4231-4236.
127. Moore JS, et al. Oral epithelial cells are susceptible to cell-free and cell-associated HIV-1 infection in vitro. Virology 2003;313:343-353.
128. Colasante A, Rosini S, Piattelli A, Artese L, Aiello FB, Musiani P. Distribution and phenotype of immune cells in normal human gingiva: active immune response versus unresponsiveness. J Oral Pathol Med 1992;21:12-16.
129. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995;85:475-484.
130. van Loon LA, Krieg SR, Davidson CL, Bos JD. Quantification and distribution of lymphocyte subsets and Langerhans cells in normal human oral mucosa and skin. J Oral Pathol Med 1989;18:197-201.
131. Jotwani R, Cutler CW. Multiple dendritic cell (DC) subpopulations in human gingiva and association of mature DCs with CD4+ T-cells in situ. J Dent Res 2003;82:736-741.
132. Kawamura T, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 2003;100:8401-8406.
133. Ballweber L, et al. Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J Virol 2011;85:13443-13447.
134. Hladik F, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007;26:257-270.
135. de Jong MA, et al. Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors. J Leukoc Biol 2010;87:637-643.
136. Geijtenbeek TB, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
137. Russell ES, et al. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. AIDS Res Hum Retroviruses 2013;29:511-515.
138. Rychert J, Lacour N, Amedee AM. Genetic analysis of simian immunodeficiency virus expressed in milk and selectively transmitted through breastfeeding. J Virol 2006;80:3721-3731.
139. Greenier JL, Van Rompay KK, Montefiori D, Earl P, Moss B, Marthas ML. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol J 2005;2:11.
140. Liu J, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010;84:10406-10412.
141. Varela M, et al. Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection. J Virol 2011;85:10332-10345.
142. Ceballos A, et al. Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding. J Gen Virol 2008;89:2773-2782.
143. Becquart P, et al. Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology 2002;300:109-117.
144. Becquart P, Courgnaud V, Willumsen J, Van de Perre P. Diversity of HIV-1 RNA and DNA in breast milk from HIV-1-infected mothers. Virology 2007;363:256-260.
145. Gray RR, et al. Multiple independent lineages of HIV-1 persist in breast milk and plasma. AIDS 2011;25:143-152.
146. Henderson GJ, et al. HIV-1 populations in blood and breast milk are similar. Virology 2004;330:295-303.
147. Permar SR, et al. Local replication of simian immunodeficiency virus in the breast milk compartment of chronically-infected, lactating rhesus monkeys. Retrovirology 2010;7:7.
148. Haaland RE, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009;5:e1000274.
149. Archibald DW, Cole GA. In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res Hum Retroviruses 1990;6:1425-1432.
150. Baron S, Poast J, Cloyd MW. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med 1999;159:303-310.
151. Bolscher JG, et al. Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. Eur J Oral Sci 2002;110:149-156.
152. Fultz PN. Components of saliva inactivate human immunodeficiency virus. Lancet 1986;2:1215.
153. Malamud D, Davis C, Berthold P, Roth E, Friedman H. Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses 1993;9:633-637.
154. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-464.
155. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D. Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997;13:371-376.
156. Robinovitch MR, Ashley RL, Iversen JM, Vigoren EM, Oppenheim FG, Lamkin M. Parotid salivary basic proline-rich proteins inhibit HIV-I infectivity. Oral Dis 2001;7:86-93.
157. Robinovitch MR, Iversen JM, Resnick L. Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus. Crit Rev Oral Biol Med 1993;4:455-459.
158. Yeh CK, Handelman B, Fox PC, Baum BJ. Further studies of salivary inhibition of HIV-1 infectivity. J Acquir Immune Defic Syndr 1992;5:898-903.
159. Bergey EJ, et al. Aggregation of human immunodeficiency virus type 1 by human salivary secretions. Crit Rev Oral Biol Med 1993;4:467-474.
160. Crombie R. Mechanism of thrombospondin-1 anti-HIV-1 activity. AIDS Patient Care STDs 2000;14:211-214.
161. Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med 1998;187:25-35.
162. Bergey EJ, et al. Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr 1994;7:995-1002.
163. Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J 2006;3:99.
164. Saeland E, de Jong MA, Nabatov AA, Kalay H, Geijtenbeek TB, van Kooyk Y. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol 2009;46:2309-2316.
165. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis 1998;178:1635-1641.
166. Malamud D, et al. Inhibition of HIV infectivity by human saliva. Oral Dis 1997;3(Suppl 1):S58-S63.
167. Wu Z, et al. Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses 2003;19:201-209.
168. Harmsen MC, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995;172:380-388.
169. Kazmi SH, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006;13:1111-1118.
170. Swart PJ, et al. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses 1996;12:769-775.
171. Henrick BM, Nag K, Yao XD, Drannik AG, Aldrovandi GM, Rosenthal KL. Milk matters: soluble Toll-like receptor 2 (sTLR2) in breast milk significantly inhibits HIV-1 infection and inflammation. PLoS ONE 2012;7:e40138.
172. Lohman-Payne B, et al. Breast milk cellular HIV-specific interferon gamma responses are associated with protection from peripartum HIV transmission. AIDS 2012;26:2007-2016.
173. Arsenault JE, Webb AL, Koulinska IN, Aboud S, Fawzi WW, Villamor E. Association between breast milk erythropoietin and reduced risk of mother-to-child transmission of HIV. J Infect Dis 2010;202:370-373.
174. Walter J, et al. High concentrations of interleukin 15 in breast milk are associated with protection against postnatal HIV transmission. J Infect Dis 2009;200:1498-1502.
175. Villamor E, et al. Long-chain n-6 polyunsaturated fatty acids in breast milk decrease the risk of HIV transmission through breastfeeding. Am J Clin Nutr 2007;86:682-689.
176. Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine MD, Belec L. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol 2000;7:515-518.
177. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997;90:1141-1149.
178. Skott P, Lucht E, Ehnlund M, Bjorling E. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Oral Dis 2002;8:160-167.
179. Farquhar C, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002;186:1173-1176.
180. Becquart P, Gresenguet G, Hocini H, Kazatchkine MD, Belec L. Secretory leukocyte protease inhibitor in colostrum and breast milk is not a major determinant of the protection of early postnatal transmission of HIV. AIDS 1999;13:2599-2602.
181. Ma G, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004;200:1337-1346.
182. Bonass WA, High AS, Owen PJ, Devine DA. Expression of beta-defensin genes by human salivary glands. Oral Microbiol Immunol 1999;14:371-374.
183. Dale BA, et al. Localized antimicrobial peptide expression in human gingiva. J Periodontal Res 2001;36:285-294.
184. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002;110:121-124.
185. Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect Immun 1998;66:4222-4228.
186. Mathews M, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999;67:2740-2745.
187. O'Neil DA, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718-6724.
188. Sahasrabudhe KS, Kimball JR, Morton TH, Weinberg A, Dale BA. Expression of the antimicrobial peptide, human beta-defensin 1, in duct cells of minor salivary glands and detection in saliva. J Dent Res 2000;79:1669-1674.
189. Zhao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996;396:319-322.
190. Quinones-Mateu ME, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003;17:F39-F48.
191. Sun L, et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 2005;79:14318-14329.
192. Mackewicz CE, et al. alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 2003;17:F23-F32.
193. Zhang L, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002;298: 995-1000.
194. Kuhn L, et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 2005;39:138-142.
195. Cole AM, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002;99:1813-1818.
196. Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003;170:4708-4716.
197. Wang W, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004;173:515-520.
198. Martin V, Maldonado A, Fernandez L, Rodriguez JM, Connor RI. Inhibition of human immunodeficiency virus type 1 by lactic acid bacteria from human breastmilk. Breastfeed Med 2010;5:153-158.
199. Tomas MS, Claudia OM, Ocana V, Elena Nader-Macias M. Production of antimicrobial substances by lactic acid bacteria I: determination of hydrogen peroxide. Methods Mol Biol 2004;268:337-346.
200. Pourtois M, Binet C, Van Tieghem N, Courtois PR, Vandenabbeele A, Thirty L. Saliva can contribute in quick inhibition of HIV infectivity. AIDS 1991;5:598-600.
201. Iqbal SM, et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005;192:728-738.
202. Taborda-Vanegas N, Zapata W, Rugeles MT. Genetic and immunological factors involved in natural resistance to HIV-1 infection. Open Virol J 2011;5:35-43.
203. Mackelprang RD, et al. Maternal HLA homozygosity and mother-child HLA concordance increase the risk of vertical transmission of HIV-1. J Infect Dis 2008;197:1156-1161.
204. Baba TW, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206.
205. Hofmann-Lehmann R, et al. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol 2002;31:109-119.
206. Van de Perre P, et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet 1993;341:914-918.
207. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012;8:e1002739.
208. Hasselrot K, et al. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 2009;23:329-333.
209. Farquhar C, et al. Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya. Clin Exp Immunol 2008;153:37-43.
210. Kuhn L, et al. Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr 2006;149:611-616.
211. Becquart P, Hocini H, Levy M, Sepou A, Kazatchkine MD, Belec L. Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 2000;181: 532-539.
212. Hocini H, et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 1997;13: 1179-1185.
213. Chomont N, et al. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology 2008;370: 246-254.
214. Bomsel M, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998;9:277-287.
215. John-Stewart GC, et al. HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis 2009;199:889-898.
216. Lohman-Payne B, et al. Infants with late breast milk acquisition of HIV-1 generate interferon-gamma responses more rapidly than infants with early peripartum acquisition. Clin Exp Immunol 2009;156:511-517.
217. Kuhn L, et al. T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS 2001;15:1-9.
218. Taha TE. Mother-to-child transmission of HIV-1 in sub-Saharan Africa: past, present and future challenges. Life Sci 2011;88:917-921.
219. Averbach SH, et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010;24:1035-1042.
220. Johnson KE, et al. Effects of HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda. J Infect Dis 2011;203:602-609.
221. Johnson KE, et al. Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 2009;23:1807-1815.
222. Laga M, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994;344:246-248.
223. Laga M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
224. Reynolds SJ, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006;82: 121-126.
225. Reynolds SJ, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003;187:1513-1521.
226. van de Wijgert JH, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis 2009;36:357-364.
227. Van Der Pol B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008;197:548-554.
228. Embree JE, et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 2000;14:2535-2541.
229. Faruque S, et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:87-92.
230. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J Infect Dis 2009;199:1318-1322.
231. Koning FA, et al. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol 2005;175:6117-6122.
232. Lajoie J, et al. A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol 2012;5:277-287.
233. McLaren PJ, et al. HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J Infect Dis 2010;202(Suppl 3):S339-S344.
234. Lane BR, et al. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol 2001;75:8195-8202.
235. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86:2336-2340.
236. Poli G, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990;172:151-158.
237. Poli G, et al. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-785.
238. Giavedoni LD, et al. Impact of mucosal inflammation on oral simian immunodeficiency virus transmission. J Virol 2013;87:1750-1758.
239. Buchbinder SP, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-1893.
240. Rollins NC, Filteau SM, Coutsoudis A, Tomkins AM. Feeding mode, intestinal permeability, and neopterin excretion: a longitudinal study in infants of HIV-infected South African women. J Acquir Immune Defic Syndr 2001;28:132-139.
241. Rossenkhan R, et al. Infant feeding practices were not associated with breast milk HIV-1 RNA levels in a randomized clinical trial in Botswana. AIDS Behav 2012;16:1260-1264.
242. Fiocchi A, Assa'ad A, Bahna S. Food allergy and the introduction of solid foods to infants: a consensus document. Adverse Reactions to Foods Committee, American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2006;97:10-20.; quiz 1, 77.
243. Kramer MS, Kakuma R. The optimal duration of exclusive breastfeeding: a systematic review. Adv Exp Med Biol 2004;554:63-77.
244. Scariati PD, Grummer-Strawn LM, Fein SB. A longitudinal analysis of infant morbidity and the extent of breastfeeding in the United States. Pediatrics 1997;99:E5.
245. Silvestri G, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 2005;79:4043-4054.
246. Silvestri G, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003;18:441-452.
247. Sumpter B, et al. Correlates of preserved CD4(+) T cell homeostasis during natural, nonpathogenic simian immunodeficiency virus infection of sooty mangabeys: implications for AIDS pathogenesis. J Immunol 2007;178:1680-1691.
248. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
249. Gordon SN, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007;179:3026-3034.
250. Bosinger SE, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009;119:3556-3572.
251. Estes JD, et al. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 2008;180:6798-6807.
252. Okoye A, et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 2007;204:2171-2185.
253. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008;22:439-446.
254. Chahroudi A, Meeker T, Lawson B, Ratcliffe S, Else J, Silvestri G. Mother-to-infant transmission of simian immunodeficiency virus is rare in sooty mangabeys and is associated with low viremia. J Virol 2011;85:5757-5763.
255. Otsyula MG, Gettie A, Suleman M, Tarara R, Mohamed I, Marx P. Apparent lack of vertical transmission of simian immunodeficiency virus (SIV) in naturally infected African green monkeys, Cercopithecus aethiops. Ann Trop Med Parasitol 1995;89:573-576.
256. Pandrea I, et al. Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol 2008;82:5501-5509.
257. Phillips-Conroy JE, Jolly CJ, Petros B, Allan JS, Desrosiers RC. Sexual transmission of SIVagm in wild grivet monkeys. J Med Primatol 1994;23:1-7.
258. Amedee AM, Lacour N, Ratterree M. Mother-to-infant transmission of SIV via breast-feeding in rhesus macaques. J Med Primatol 2003;32:187-193.
259. Amedee AM, Rychert J, Lacour N, Fresh L, Ratterree M. Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 2004;1:17.
260. Santiago ML, et al. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 2005;79:12515-12527.
261. Wilks AB, et al. High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys. J Virol 2011;85:9517-9526.
262. Pandrea I, et al. Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 2007;109:1069-1076.
263. Paiardini M, et al. Low levels of SIV infection in sooty mangabey central memory CD(4)(+) T cells are associated with limited CCR5 expression. Nat Med 2011;17:830-836.
264. Pandrea I, et al. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012;120:1357-1366.
265. Beer B, et al. Simian immunodeficiency virus of African green monkeys is apathogenic in the newborn natural host. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:210-220.
266. Mofenson LM. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 2010;15:537-553.
267. Persaud D, et al. Functional HIV Cure after Very Early ART of an Infected Infant. Atlanta, Georgia: Conference on Retroviruses and Opportunistic Infections, 2013.
268. Borkow G, Lara HH, Covington CY, Nyamathi A, Gabbay J. Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters. Antimicrob Agents Chemother 2008;52:518-525.
269. Gerrard SE, et al. Reducing infectivity of HIV upon exposure to surfaces coated with N, N-dodecyl, methyl-polyethylenimine. Biotechnol Bioeng 2013; doi: 10.1002/bit.24867.
270. Israel-Ballard K, et al. Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries. J Acquir Immune Defic Syndr 2007;45:318-323.
271. Jeffery BS, Webber L, Mokhondo KR, Erasmus D. Determination of the effectiveness of inactivation of human immunodeficiency virus by Pretoria pasteurization. J Trop Pediatr 2001;47:345-349.
272. Urdaneta S, et al. Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS). Retrovirology 2005;2:28.
273. Volk ML, Hanson CV, Israel-Ballard K, Chantry CJ. Inactivation of cell-associated and cell-free HIV-1 by flash-heat treatment of breast milk. J Acquir Immune Defic Syndr 2010;53:665-666.
274. Chantry CJ, et al. Effect of flash-heat treatment on immunoglobulins in breast milk. J Acquir Immune Defic Syndr 2009;51:264-267.
275. Ferrantelli F, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004;189:2167-2173.
276. Van Rompay KK, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005;38:124-134.
277. Marthas ML, et al. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 2011;29:3124-3137.
278. Van Rompay KK, et al. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 2010;28:1481-1492.
279. Mumcu G, et al. Salivary levels of antimicrobial peptides Hnp 1-3, Ll-37 and S100 in Behcet's disease. Arch Oral Biol 2012;57:642-646.
280. Ghosh SK, Gerken TA, Schneider KM, Feng Z, McCormick TS, Weinberg A. Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem 2007;53:757-765.
281. Hasselrot K, Bratt G, Duvefelt K, Hirbod T, Sandstrom E, Broliden K. HIV-1 exposed uninfected men who have sex with men have increased levels of salivary CC-chemokines associated with sexual behavior. AIDS 2010;24:1569-1575.
282. Hung GY, Jeng MJ, Lin CY, Soong WJ, Hwang B. The relationship between serum and saliva erythropoietin concentrations in adults, full-term and premature infants. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1998;39:380-385.
283. Dalvi MS, Abrams WR, Barber CA, Norman R, Malamud D. Salivary and Plasma Cytokine Alterations in HIV Infection. San Diego: IADR/AADR/CADR 89th General Session and Exhibition, 2011.
284. Actis AB, Perovic NR, Defago D, Beccacece C, Eynard AR. Fatty acid profile of human saliva: a possible indicator of dietary fat intake. Arch Oral Biol 2005;50:1-6.
285. Sanchez GA, Miozza V, Delgado A, Busch L. Determination of salivary levels of mucin and amylase in chronic periodontitis patients. J Periodontal Res 2011;46:221-227.